You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb1805469 |
---|---|
Category | Antibodies |
Description | Anti-CD79b Reference Antibodyected antibody and Monomethyl auristatin E (MMAE) that can be used in combination with bendamustine and rituximab for the treatment of adult patients with at least two relapses or refractory diffuse large B-cell lymphoma. Polatuzumab vedotin binds to CD79b and is internalized by tumor cells. MMAE is cleaved from cells by lysosomal protease and promotes tumor cell apoptosis by inhibiting microtubule formation. |
Clonality | Monoclonal |
Tested applications | ELISA, FA, FACS, Kinetics |
Reactivity | Human |
Isotype | IgG |
Purity | > 95% |
Conjugation | Unconjugated |
MW | 145.5 kDa |
Target | CD79b |
Endotoxins | < 1 EU/mg |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Buffer/Preservatives | 100 mM Pro-Ac 20 mM Arg pH 5.0 |
Note | For research use only |
Expiration Date | 12 months from date of receipt. |
Anti-CD79b Reference Antibody (polatuzumab vedotin-piiq) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Anti-CD79b Reference Antibody (polatuzumab vedotin-piiq)is more than 95% ;determined by SEC-HPLC.
Immobilized human CD79b; His Tag at 2 μg/mL can bind Anti-CD79b Reference Antibody (polatuzumab vedotin-piiq);EC50=0.005029μg/mL.
ELISA, FC | |
Human | |
Monoclonal | |
Unconjugated |